Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Mross

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Onkologie|July 7, 2001
Phase I Clinical Trial of a Day-1, -3, -5 Every 3 WeeksPhase I Clinical Trial of Day-1, -3, -5 Every 3 Weeks Schedule with Titanocene Dichloride (MKT 5) in Patients with Advanced Cancer. (Phase I Study Group of the AIO of the German Cancer Society)K. Mross, P. Robben-Bathe, L. Edler, et al.
Bone Marrow Transplantation|April 1, 1994
Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusionK Mross, P Bewermeier, J Reifke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2011
Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasisU Fasol, A Frost, M Büchert, et al.
Anti-Cancer Drugs|July 27, 2000
Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patientsL van Zuylen, L Gianni, J Verweij, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 1998
Clinical phase I study with one-hour paclitaxel infusionK Mross, B Hauns, B Häring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1988
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humansK Mross, P Maessen, W J van der Vijgh, et al.
Current Oncology (Toronto, Ont.)|February 14, 2012
Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumoursA Frost, K Mross, S Steinbild, et al.
Annals of Hematology|February 1, 1993
Monoclonal gammopathy of unknown significance in a bone marrow donorS O Peters, M Stockschläder, W Zeller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 1999
Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer SocietyK Mross, W E Berdel, H H Fiebig, et al.
Analytical Biochemistry|August 26, 1998
Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusionsE Brouwer, J Verweij, B Hauns, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Onkologie|July 7, 2001
Phase I Clinical Trial of a Day-1, -3, -5 Every 3 WeeksPhase I Clinical Trial of Day-1, -3, -5 Every 3 Weeks Schedule with Titanocene Dichloride (MKT 5) in Patients with Advanced Cancer. (Phase I Study Group of the AIO of the German Cancer Society)K. Mross, P. Robben-Bathe, L. Edler, et al.
Bone Marrow Transplantation|April 1, 1994
Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusionK Mross, P Bewermeier, J Reifke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2011
Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasisU Fasol, A Frost, M Büchert, et al.
Anti-Cancer Drugs|July 27, 2000
Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patientsL van Zuylen, L Gianni, J Verweij, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 1998
Clinical phase I study with one-hour paclitaxel infusionK Mross, B Hauns, B Häring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1988
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humansK Mross, P Maessen, W J van der Vijgh, et al.
Current Oncology (Toronto, Ont.)|February 14, 2012
Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumoursA Frost, K Mross, S Steinbild, et al.
Annals of Hematology|February 1, 1993
Monoclonal gammopathy of unknown significance in a bone marrow donorS O Peters, M Stockschläder, W Zeller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 1999
Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer SocietyK Mross, W E Berdel, H H Fiebig, et al.
Analytical Biochemistry|August 26, 1998
Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusionsE Brouwer, J Verweij, B Hauns, et al.
Pageof 7